Ventura County hospitals, clinics, health plan will pay $70.7M to settle claims of improper billing
NOTE: This article was posted Aug. 18 and updated Aug. 26 with more details about the allegedly improper billing practices. The complete settlement agreements were also added and are viewable at the bottom of this article. Three medical providers and one health coverage system in Ventura County have agreed to pay a total of $70.7 Read More →
Sientra lowers guidance, shares drop 20%
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind reports Q2 loss but beats revenue expectations
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara announces plan to cut workforce by 20%
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Inogen beats Q2 estimates, but shares still drop
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen beats analysts’ expectations for earnings and revenue in Q2
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen to buy ChemoCentryx for $3.7B
Amgen was having a relatively quiet year on the mergers and acquisitions front, at least until Aug. 4, when the Thousand Oaks-based biotech firm announced it will purchase ChemoCentryx for nearly $3.7 billion. ChemoCentryx is a Silicon Valley biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has Read More →
